LASHEN, A. G., TOSS, M. S., WOOTTON, L., GREEN, A. R., MONGAN, N. P., MADHUSUDAN, S. and RAKHA, E., 2023. Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer: Histopathology Histopathology. ALGETHAMI, M., TOSS, M. S., WOODCOCK, C. L., JAIPAL, C., BROWNLIE, J., SHOQAFI, A., ALBLIHY, A., MESQUITA, K. A., GREEN, A. R., MONGAN, N. P., JEYAPALAN, J. N., RAKHA, E. A. and MADHUSUDAN, S., 2023. Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers: NPJ Breast Cancer NPJ Breast Cancer. 9(1), 18 CHARLES COOMBES, HEMMEL AMRANIA, CHRISTINA ANGELOU, ZAMZAM AL-KHALILI, IAN O. ELLIS, DARIUS FRANCESCATTI, CHRIS PHILLIPS, ANDREW R. GREEN, NICHOLAS WRIGHT, EMAD A. RAKHA and CARLO PALMIERI, 2023. Validation of a novel and rapid reagent free assay to predict outcomes for adjuvant therapy decision making in hormone receptor-positive breast cancer. Journal of Clinical Oncology. 41, SHOROUK MAKHLOUF, MARYAM ALTHOBITI, MICHAEL TOSS, ABIR A. MUFTAH, NIGEL P. MONGAN, ANDREW H.S. LEE, ANDREW R. GREEN and EMAD A. RAKHA, 2023. The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer Modern Pathology. 36, SARAH J. STORR, VICTORIA HOSKIN, RADHIKA AIYAPPA-MAUDSLEY, ABDI GHAFFARI, SONAL VARMA, ANDREW GREEN, EMAD RAKHA, IAN O. ELLIS, PETER A. GREER and STEWART G. MARTIN, 2023. A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease Cancer Medicine. 12, AYAT G. LASHEN, MICHAEL S. TOSS, LOUISA WOOTTON, ANDREW R. GREEN, NIGEL P. MONGAN, SRINIVASAN MADHUSUDAN and EMAD RAKHA, 2023. Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer Histopathology. 83, MASHAEL ALGETHAMI, MICHAEL S. TOSS, CORINNE L. WOODCOCK, CHANDAR JAIPAL, JULIETTE BROWNLIE, AHMED SHOQAFI, ADEL ALBLIHY, KATIA A. MESQUITA, ANDREW R. GREEN, NIGEL P. MONGAN, JENNIE N. JEYAPALAN, EMAD A. RAKHA and SRINIVASAN MADHUSUDAN, 2023. Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers npj Breast Cancer. 9, ISLAM M. MILIGY, MICHAEL S. TOSS, KYLIE L. GORRINGE, IAN O. ELLIS, ANDREW R. GREEN and EMAD A. RAKHA, 2022. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ Pathobiology. 89, SAMI A. ALSAEED, MICHAEL TOSS, MANSOUR ALSALEEM, MOHAMMED ALESKANDARANY, CHITRA JOSEPH, SASAGU KUROZUMI, GRAHAM BALL, NIGEL MONGAN, ANDREW GREEN and EMAD RAKHA, 2022. Prognostic significance of heat shock protein 90AA1 (HSP90α) in invasive breast cancer Journal of Clinical Pathology. 75, YOUSIF A. KARIRI, CHITRA JOSEPH, MANSOUR A. ALSALEEM, KHLOUD A. ELSHARAWY, SAMI ALSAEED, MICHAEL S. TOSS, NIGEL P. MONGAN, ANDREW R. GREEN and EMAD A. RAKHA, 2022. Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer Cancers. 14, AYAT LASHEN, MICHAEL S. TOSS, MANSOUR ALSALEEM, ANDREW R. GREEN, NIGEL P. MONGAN and EMAD RAKHA, 2022. The characteristics and clinical significance of atypical mitosis in breast cancer Modern Pathology. 35, NEHAL M. ATALLAH, MICHAEL S. TOSS, ANDREW R. GREEN, NIGEL P. MONGAN, GRAHAM BALL and EMAD A. RAKHA, 2022. Refining the definition of HER2-low class in invasive breast cancer Histopathology. 81, AYAT LASHEN, MICHAEL S. TOSS, ANDREW R. GREEN, NIGEL P. MONGAN and EMAD RAKHA, 2022. Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods Histopathology. 81, JODI M. SAUNUS, XAVIER M. DE LUCA, KORINNE NORTHWOOD, ASHWINI RAGHAVENDRA, ALEXANDER HASSON, AMY E. MCCART REED, MALCOLM LIM, SAMIR LAL, A. CRISTINA VARGAS, JAMIE R. KUTASOVIC, ANDREW J. DALLEY, MARISKA MIRANDA, EMARENE KALAW, PRIYAKSHI KALITA-DE CROFT, IRMA GRESSHOFF, FARES AL-EJEH, JULIA M.W. GEE, CHRIS ORMANDY, KUM KUM KHANNA, JONATHAN BEESLEY, GEORGIA CHENEVIX-TRENCH, ANDREW R. GREEN, EMAD A. RAKHA, IAN O. ELLIS, DAN V. NICOLAU, PETER T. SIMPSON and SUNIL R. LAKHANI, 2022. Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer npj Breast Cancer. 8, YOUSIF KARIRI, MICHAEL S. TOSS, MANSOUR ALSALEEM, KHLOUD A. ELSHARAWY, CHITRA JOSEPH, NIGEL P. MONGAN, ANDREW R. GREEN and EMAD A. RAKHA, 2022. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer Breast Cancer Research and Treatment. 192, SYED, BINAFSHA M., GREEN, ANDREW R., RAKHA, EMAD A., MORGAN, DAVID A. L., ELLIS, IAN O. and CHEUNG, KWOK-LEUNG, 2021. Age-Related Biology of Early-Stage Operable Breast Cancer and Its Impact on Clinical Outcome CANCERS. 13(6), SAIDY, BEHNAZ, KOTECHA, SHREEYA, BUTLER, ANNA, RAKHA, EMAD A., ELLIS, IAN O., GREEN, ANDREW R., MARTIN, STEWART G. and STORR, SARAH J., 2021. PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression Journal of Cellular and Molecular Medicine. 25(11), 5015-5024 ALTHOBITI, MARYAM, EL-SHARAWY, KHLOUD A., JOSEPH, CHITRA, ALESKANDARANY, MOHAMMED, TOSS, MICHAEL S., GREEN, ANDREW R. and RAKHA, EMAD A., 2021. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer BREAST CANCER RESEARCH AND TREATMENT. 189(3), 621-630 SAVVA, CONSTANTINOS, SADIQ, MAAZ, SHEIKH, OMAR, KARIM, SYED, TRIVEDI, SACHIN, GREEN, ANDREW R, RAKHA, EMAD A, MADHUSUDAN, SRINIVASAN and ARORA, ARVIND, 2021. Werner syndrome protein expression in breast cancer Clinical Breast Cancer. 21(1), 57-73
JODI M. SAUNUS, XAVIER M. DE LUCA, KORINNE NORTHWOOD, ASHWINI RAGHAVENDRA, ALEXANDER HASSON, AMY E. MCCART REED, MALCOLM LIM, SAMIR LAL, ANA CRISTINA VARGAS, JAMIE R. KUTASOVIC, ANDREW J. DALLEY, MARISKA MIRANDA, EMARENE KALAW, PRIYAKSHI KALITA-DE CROFT, IRMA GRESSHOFF, FARES AL-EJEH, JULIA M.W. GEE, CHRIS ORMANDY, KUM KUM KHANNA, JONATHAN BEESLEY, GEORGIA CHENEVIX-TRENCH, ANDREW R. GREEN, EMAD A. RAKHA, IAN O. ELLIS, DAN V. NICOLAU, PETER T. SIMPSON and SUNIL R. LAKHANI, 2021. Epigenome erosion drives neural crest-like phenotypic mimicry in triple-negative breast cancer and other SOX10+ malignancies bioRxiv.
BRENDAH K. MASISI, ROKAYA EL ANSARI, LUTFI ALFARSI, MADELEINE L. CRAZE, NATASHA JEWA, ANDREW OLDFIELD, HAYLEY CHEUNG, MICHAEL TOSS, EMAD A. RAKHA and ANDREW R. GREEN, 2021. The biological and clinical significance of glutaminase in luminal breast cancer Cancers. 13, KHLOUD A. ELSHARAWY, MARYAM ALTHOBITI, OMAR J. MOHAMMED, ABRAR I. ALJOHANI, MICHAEL S. TOSS, ANDREW R. GREEN and EMAD A. RAKHA, 2021. Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer Breast Cancer Research and Treatment. 185, YOUSIF A. KARIRI, MANSOUR ALSALEEM, CHITRA JOSEPH, SAMI ALSAEED, ABRAR ALJOHANI, SHO SHIINO, OMAR J. MOHAMMED, MICHAEL S. TOSS, ANDREW R. GREEN and EMAD A. RAKHA, 2021. The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer Breast Cancer Research and Treatment. 185, MATTEO MOROTTI, CHRISTOS E. ZOIS, ROKAYA EL-ANSARI, MADELEINE L. CRAZE, EMAD A. RAKHA, SHIH JUNG FAN, ALESSANDRO VALLI, SYED HAIDER, DEBORAH C.I. GOBERDHAN, ANDREW R. GREEN and ADRIAN L. HARRIS, 2021. Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer British Journal of Cancer. 124, MARYAM ALTHOBITI, KHLOUD A. EL-SHARAWY, CHITRA JOSEPH, MOHAMMED ALESKANDARANY, MICHAEL S. TOSS, ANDREW R. GREEN and EMAD A. RAKHA, 2021. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer Breast Cancer Research and Treatment. 189, BINAFSHA M. SYED, ANDREW R. GREEN, EMAD A. RAKHA, DAVID A.L. MORGAN, IAN O. ELLIS and KWOK LEUNG CHEUNG, 2021. Age-related biology of early-stage operable breast cancer and its impact on clinical outcome Cancers. 13, BEHNAZ SAIDY, SHREEYA KOTECHA, ANNA BUTLER, EMAD A. RAKHA, IAN O. ELLIS, ANDREW R. GREEN, STEWART G. MARTIN and SARAH J. STORR, 2021. PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression Journal of Cellular and Molecular Medicine. 25, CONSTANTINOS SAVVA, MAAZ SADIQ, OMAR SHEIKH, SYED KARIM, SACHIN TRIVEDI, ANDREW R. GREEN, EMAD A. RAKHA, SRINIVASAN MADHUSUDAN and ARVIND ARORA, 2021. Werner Syndrome Protein Expression in Breast Cancer Clinical Breast Cancer. 21, MICHAEL S. TOSS, ASIMA ABIDI, DOROTHEA LESCHE, CHITRA JOSEPH, SAKSHI MAHALE, HUGO SAUNDERS, TANJINA KADER, ISLAM M. MILIGY, ANDREW R. GREEN, KYLIE L. GORRINGE & EMAD A. RAKHA, 2020. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ British Journal of Cancer. ALFARSI, L. H., EL ANSARI, R., MASISI, B. K., PARKS, R., MOHAMMED, O. J., ELLIS, I. O., RAKHA, E. A. and GREEN, A. R., 2020. Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer: Cancers (Basel) Cancers (Basel). 12(6), ALFARSI, L. H., EL ANSARI, R., CRAZE, M. L., MASISI, B. K., ELLIS, I. O., RAKHA, E. A. and GREEN, A. R., 2020. PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer: BMC Cancer BMC Cancer. 20(1), 425 ALFARSI, L. H., EL-ANSARI, R., CRAZE, M. L., MASISI, B. K., MOHAMMED, O. J., ELLIS, I. O., RAKHA, E. A. and GREEN, A. R., 2020. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer: Int J Mol Sci Int J Mol Sci. 21(4), KHLOUD A. ELSHARAWY, MICHAEL S. TOSS, SARA RAAFAT, GRAHAM BALL, ANDREW R. GREEN, MOHAMMED A. ALESKANDARANY, LESLIE W. DALTON and EMAD A. RAKHA, 2020. Prognostic significance of nucleolar assessment in invasive breast cancer Histopathology. 76, SASAGU KUROZUMI, MANSOUR ALSALEEM, CÍNTIA J. MONTEIRO, KARTIKEYA BHARDWAJ, STACEY E.P. JOOSTEN, TAKAAKI FUJII, KEN SHIRABE, ANDREW R. GREEN, IAN O. ELLIS, EMAD A. RAKHA, NIGEL P. MONGAN, DAVID M. HEERY, WILBERT ZWART, STEFFI OESTERREICH and SIMON J. JOHNSTON, 2020. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: A retrospective in silico analysis of public datasets Breast Cancer Research. 22, MICHAEL S. TOSS, ASIMA ABIDI, DOROTHEA LESCHE, CHITRA JOSEPH, SAKSHI MAHALE, HUGO SAUNDERS, TANJINA KADER, ISLAM M. MILIGY, ANDREW R. GREEN, KYLIE L. GORRINGE and EMAD A. RAKHA, 2020. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ British Journal of Cancer. 122, SASAGU KUROZUMI, SAMI ALSAEED, NNAMDI ORAH, ISLAM M. MILIGY, CHITRA JOSEPH, ABRAR ALJOHANI, MICHAEL S. TOSS, TAKAAKI FUJII, KEN SHIRABE, ANDREW R. GREEN, MOHAMMED A. ALESKANDARANY and EMAD A. RAKHA, 2020. Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer Breast Cancer Research and Treatment. 179, MICHAEL TOSS, ISLAM MILIGY, KYLIE GORRINGE, KARUNA MITTAL, RITU ANEJA, IAN ELLIS, ANDREW GREEN and EMAD RAKHA, 2020. Prognostic significance of cathepsin v (CTSV/CTSL2) in breast ductal carcinoma in situ Journal of Clinical Pathology. 73, KHLOUD A. ELSHARAWY, OMAR J. MOHAMMED, MOHAMMED A. ALESKANDARANY, AYMAN HYDER, HEKMAT L. EL-GAMMAL, MOHAMED I. ABOU-DOBARA, ANDREW R. GREEN, LESLIE W. DALTON and EMAD A. RAKHA, 2020. The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer British Journal of Cancer. 123, JOSEPH C, AL-IZZI S, ALSALEEM M, KUROZUMI S, TOSS MS, ARSHAD M, GOH FQ, ALSHANKYTY IM, ALESKANDARANY MA, ALI S, ELLIS IO, MONGAN NP, GREEN AR and RAKHA EA, 2019. Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. British journal of cancer. 121(9), 776-785 ALFARSI, L. H., ELANSARI, R., TOSS, M. S., DIEZ-RODRIGUEZ, M., NOLAN, C. C., ELLIS, I. O., RAKHA, E. A. and GREEN, A. R., 2019. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer: Breast Cancer Res Treat Breast Cancer Res Treat. 173(1), 93-102 ABDEL-FATAH, T. M. A., BROOM, R. J., LU, J., MOSELEY, P. M., HUANG, B., LI, L., LIU, S., CHEN, L., MA, R. Z., CAO, W., WANG, X., LI, Y., PERRY, J. K., ALESKANDARANY, M., NOLAN, C. C., RAKHA, E. A., LOBIE, P. E., CHAN, S. Y. T., ELLIS, I. O., HWANG, L. A., LANE, D. P., GREEN, A. R. and LIU, D. X., 2019. SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment: Br J Cancer Br J Cancer. 120(7), 728-745 EL-ANSARI, R., CRAZE, M. L., ALFARSI, L., SORIA, D., DIEZ-RODRIGUEZ, M., NOLAN, C. C., ELLIS, I. O., RAKHA, E. A. and GREEN, A. R., 2019. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer: Breast Cancer Res Treat Breast Cancer Res Treat. 175(1), 27-38 ABDEL-FATAH, T. M. A., ALI, R., SADIQ, M., MOSELEY, P. M., MESQUITA, K. A., BALL, G., GREEN, A. R., RAKHA, E. A., CHAN, S. Y. T. and MADHUSUDAN, S., 2019. ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers: Cancers (Basel) Cancers (Basel). 11(8), JOSEPH C., AL-IZZI S., ALSALEEM M., KUROZUMI S., TOSS M.S., ARSHAD M., GOH F.Q., ALSHANKYTY I.M., ALESKANDARANY M.A., ALI S., ELLIS I.O., MONGAN N.P., GREEN A.R. and RAKHA E.A., 2019. Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer British Journal of Cancer. 121,
TAREK M.A. ABDEL-FATAH, REUBEN J. BROOM, JUN LU, PAUL M. MOSELEY, BAIQU HUANG, LILI LI, SULING LIU, LONGXIN CHEN, RUNLIN Z. MA, WENMING CAO, XIAOJIA WANG, YAN LI, JO K. PERRY, MOHAMMED ALESKANDARANY, CHRISTOPHER C. NOLAN, EMAD A. RAKHA, PETER E. LOBIE, STEPHEN Y.T. CHAN, IAN O. ELLIS, LE ANN HWANG, DAVID P. LANE, ANDREW R. GREEN and DONG XU LIU, 2019. SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment British Journal of Cancer. 120, ROKAYA EL-ANSARI, MADELEINE L. CRAZE, LUTFI ALFARSI, DANIELE SORIA, MARIA DIEZ-RODRIGUEZ, CHRISTOPHER C. NOLAN, IAN O. ELLIS, EMAD A. RAKHA and ANDREW R. GREEN, 2019. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer Breast Cancer Research and Treatment. 175, LUTFI H. ALFARSI, ROKAYA ELANSARI, MICHAEL S. TOSS, MARIA DIEZ-RODRIGUEZ, CHRISTOPHER C. NOLAN, IAN O. ELLIS, EMAD A. RAKHA and ANDREW R. GREEN, 2019. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer Breast Cancer Research and Treatment. 173, TAREK M.A. ABDEL-FATAH, REEM ALI, MAAZ SADIQ, PAUL M. MOSELEY, KATIA A. MESQUITA, GRAHAM BALL, ANDREW R. GREEN, EMAD A. RAKHA, STEPHEN Y.T. CHAN and SRINIVASAN MADHUSUDAN, 2019. ERCC1 is a predictor of anthracycline resistance and taxane sensitivity in early stage or locally advanced breast cancers Cancers. 11, ALESKANDARANY MA, SONBUL S, SURRIDGE R, MUKHERJEE A, CALDAS C, DIEZ-RODRIGUEZ M, ASHANKYTY I, ALBRAHIM KI, ELMOUNA AM, ANEJA R, MARTIN SG, ELLIS IO, GREEN AR and RAKHA EA, 2018. Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. British journal of cancer. 117(8), 1176-1184 GONG C, MAN EP, TSOI H, LEE TK, LEE P, MA ST, WONG LS, LUK MY, RAKHA EA, GREEN AR, ELLIS IO, CHEUNG KL and KHOO US, 2018. BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen Resistant Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. (In Press.)
KUROZUMI S, JOSEPH C, SONBUL S, GORRINGE KL, PIGERA M, ALESKANDARANY MA, DIEZ-RODRIGUEZ M, NOLAN CC, FUJII T, SHIRABE K, KUWANO H, STORR S, MARTIN SG, ELLIS IO, GREEN AR and RAKHA EA, 2018. Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. Breast cancer research and treatment. 170(3), 525-533 JOSEPH C, MACNAMARA O, CRAZE M, RUSSELL R, PROVENZANO E, NOLAN CC, DIEZ-RODRIGUEZ M, SONBUL SN, ALESKANDARANY MA, GREEN AR, RAKHA EA, ELLIS IO and MUKHERJEE A, 2018. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. British journal of cancer. 118(8), 1142-1151 TOSS MS, MILIGY I, AL-KAWAZ A, ALSLEEM M, KHOUT H, RIDA PC, ANEJA R, GREEN AR, ELLIS IO and RAKHA EA, 2018. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. (In Press.)
EL ANSARI R, CRAZE ML, DIEZ-RODRIGUEZ M, NOLAN CC, ELLIS IO, RAKHA EA and GREEN AR, 2018. The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. British journal of cancer. 118(8), 1115-1122 RAKHA EA, ALESKANDARANI M, TOSS MS, GREEN AR, BALL G, ELLIS IO and DALTON LW, 2018. Breast cancer histologic grading using digital microscopy: concordance and outcome association. Journal of clinical pathology. (In Press.)
DESMEDT C, SALGADO R, FORNILI M, PRUNERI G, VAN DEN EYNDEN G, ZOPPOLI G, ROTHÉ F, BUISSERET L, GARAUD S, WILLARD-GALLO K, BROWN D, BARECHE Y, ROUAS G, GALANT C, BERTUCCI F, LOI S, VIALE G, DI LEO A, GREEN AR, ELLIS IO, RAKHA EA, LARSIMONT D, BIGANZOLI E and SOTIRIOU C, 2018. Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute. (In Press.)
DESMEDT, CHRISTINE, SALGADO, ROBERTO, FORNILI, MARCO, PRUNERI, GIANCARLO, VAN DEN EYNDEN, GERT, ZOPPOLI, GABRIELE, ROTHE, FRANCOISE, BUISSERET, LAURENCE, GARAUD, SOIZIC, WILLARD-GALLO, KAREN, BROWN, DAVID, BARECHE, YACINE, ROUAS, GHIZLANE, GALANT, CHRISTINE, BERTUCCI, FRANCOIS, LOI, SHERENE, VIALE, GIUSEPPE, DI LEO, ANGELO, GREEN, ANDREW R, ELLIS, IAN O, RAKHA, EMAD A, LARSIMONT, DENIS, BIGANZOLI, ELIA and SOTIRIOU, CHRISTOS, 2018. Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute.
TOSS M., MILIGY I., HAMAD A., NOLAN C., DIEZ-RODRIGUEZ M., ELLIS I., ALSLEEM M., GREEN A. and RAKHA E., 2018. Tumour-infiltrating lymphocytes is an independent prognostic factor in breast ductal carcinoma in situ (DCIS) Breast Cancer Research and Treatment. 167,
TOSS M.S., MILIGY I., ALKAWAZ A., NOLAN C.C., DIEZ-RODRIGUEZ M., ELLIS I.O., GREEN A.R. and RAKHA E.A., 2018. Lysosomal protective protein/Cathepsin A (CTSA) is an independent prognostic factor in breast ductal carcinoma in situ (DCIS) Journal of Pathology. 245,
TOSS M.S., MILIGY I., ALKAWAZ A., NOLAN C., RODRIGUEZ M.D., ELLIS I.O., GREEN A. and RAKHA E.A., 2018. Legumain (LGMN) is an independent poor prognostic factor in breast ductal carcinoma in situ (DCIS) Journal of Pathology. 246,
ROKAYA EL ANSARI, MADELEINE L. CRAZE, ISLAM MILIGY, MARIA DIEZ-RODRIGUEZ, CHRISTOPHER C. NOLAN, IAN O. ELLIS, EMAD A. RAKHA and ANDREW R. GREEN, 2018. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours Breast Cancer Research. 20, ROKAYA EL ANSARI, MADELEINE L. CRAZE, MARIA DIEZ-RODRIGUEZ, CHRISTOPHER C. NOLAN, IAN O. ELLIS, EMAD A. RAKHA and ANDREW R. GREEN, 2018. The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes British Journal of Cancer. 118, CHRISTINE DESMEDT, ROBERTO SALGADO, MARCO FORNILI, GIANCARLO PRUNERI, GERT VAN DEN EYNDEN, GABRIELE ZOPPOLI, FRANCOISE ROTHE, LAURENCE BUISSERET, SOIZIC GARAUD, KAREN WILLARD-GALLO, DAVID BROWN, YACINE BARECHE, GHIZLANE ROUAS, CHRISTINE GALANT, FRANCOIS BERTUCCI, SHERENE LOI, GIUSEPPE VIALE, ANGELO DI LEO, ANDREW R. GREEN, IAN O. ELLIS, EMAD A. RAKHA, DENIS LARSIMONT, ELIA BIGANZOLI and CHRISTOS SOTIRIOU, 2018. Immune infiltration in invasive lobular breast cancer Journal of the National Cancer Institute. 110, PU X, STORR SJ, ZHANG Y, RAKHA EA, GREEN AR, ELLIS IO and MARTIN SG, 2017. Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. Apoptosis : an international journal on programmed cell death. 22, 3 MUFTAH AA, ALESKANDARANY MA, AL-KAABI MM, SONBUL SN, DIEZ-RODRIGUEZ M, NOLAN CC, CALDAS C, ELLIS IO, RAKHA EA and GREEN AR, 2017. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast cancer research and treatment. (In Press.)
CHRYSANTHOU E, GORRINGE KL, JOSEPH C, CRAZE M, NOLAN CC, DIEZ-RODRIGUEZ M, GREEN AR, RAKHA EA, ELLIS IO and MUKHERJEE A, 2017. Phenotypic characterisation of breast cancer: the role of CDC42. Breast cancer research and treatment. SONBUL SN, GORRINGE KL, ALESKANDARANY MA, MUKHERJEE A, GREEN AR, ELLIS IO and RAKHA EA, 2017. Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. The journal of pathology. Clinical research. 3(2), 105-114 MILIGY I, MOHAN P, GABER A, ALESKANDARANY MA, NOLAN CC, DIEZ-RODRIGUEZ M, MUKHERJEE A, CHAPMAN C, ELLIS IO, GREEN AR and RAKHA EA, 2017. Prognostic significance of Tumour infiltrating B-Lymphocytes in Breast Ductal Carcinoma in Situ. Histopathology. 71(2), :258-268 GREEN AR, ALESKANDARANY MA, ALI R, HODGSON EG, ATABANI S, DE SOUZA K, RAKHA EA, ELLIS IO and MADHUSUDAN S, 2017. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. Cancer immunology research. 5(4), 292-299 CANDIDO DOS REIS FJ, WISHART GC, DICKS EM, GREENBERG D, RASHBASS J, SCHMIDT MK, VAN DEN BROEK AJ, ELLIS IO, GREEN A, RAKHA E, MAISHMAN T, ECCLES DM and PHAROAH PDP, 2017. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast cancer research : BCR. 19(1), 58 EL ANSARI R, MCINTYRE A, CRAZE ML, ELLIS IO, RAKHA EA and GREEN AR, 2017. Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology. (In Press.)
TOSS M, MILIGY I, THOMPSON AM, KHOUT H, GREEN AR, ELLIS IO and RAKHA EA, 2017. Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. Breast (Edinburgh, Scotland). 35, 151-156 (In Press.)
KLIMOV S, RIDA PC, ALESKANDARANY MA, GREEN AR, ELLIS IO, JANSSEN EA, RAKHA EA and ANEJA R, 2017. Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. British journal of cancer. (In Press.)
RAKHA EA, MILIGY I, GORRINGE KL, TOSS MS, GREEN AR, FOX SB, SCHMITT FC, TAN PH, TSE GM, BADVE S, DECKER T, VINCENT-SALOMON A, DABBS DJ, FOSCHINI MP, MORENO F, WENTAO Y, GEYER FC, REIS-FILHO JS, PINDER SE, LAKHANI SR and ELLIS IO, 2017. Invasion in breast lesions: the role of the epithelial-stroma barrier. Histopathology. (In Press.)
CRAZE ML, CHEUNG H, JEWA N, COIMBRA NDM, SORIA D, EL-ANSARI R, ALESKANDARANY MA, WAI CHENG K, DIEZ-RODRIGUEZ M, NOLAN CC, ELLIS IO, RAKHA EA and GREEN AR, 2017. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. British journal of cancer. (In Press.)
NAIDOO K, WAI PT, MAGUIRE SL, DALEY F, HAIDER S, KRIPLANI D, CAMPBELL J, MIRZA H, GRIGORIADIS A, TUTT A, MOSELEY PM, ABDEL-FATAH TMA, CHAN SY, MADHUSUDAN S, RAKHA EA, ELLIS IO, LORD CJ, YUAN Y, GREEN AR and NATRAJAN R, 2017. Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response Targeted Therapies in Breast Cancer. Molecular cancer therapeutics. (In Press.)
EBILI HO, IYAWE VO, ADELEKE KR, SALAMI BA, BANJO AA, NOLAN C, RAKHA E, ELLIS I, GREEN A and AGBOOLA AOJ, 2017. Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients. Molecular diagnosis & therapy. (In Press.)
AHMAD N, AMMAR A, STORR SJ, GREEN AR, RAKHA E, ELLIS IO and MARTIN SG, 2017. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer immunology, immunotherapy : CII. (In Press.)
RAKHA EA, AGARWAL D, GREEN AR, ASHANKYTY I, ELLIS IO, BALL G and ALASKANDARANY MA, 2016. Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. Histopathology. (In Press.)
LAURINAVICIUS A, PLANCOULAINE B, RASMUSSON A, BESUSPARIS J, AUGULIS R, MESKAUSKAS R, HERLIN P, LAURINAVICIENE A, ABDELHADI MUFTAH AA, MILIGY I, ALESKANDARANY M, RAKHA EA, GREEN AR and ELLIS IO, 2016. Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. Virchows Archiv : an international journal of pathology. 468(4), 493-502 ALESKANDARANY MA, AGARWAL D, NEGM OH, BALL G, ELMOUNA A, ASHANKYTY I, NUGLOZEH E, FAZALUDEEN MF, DIEZ-RODRIGUEZ M, NOLAN CC, TIGHE PJ, GREEN AR, ELLIS IO and RAKHA EA, 2016. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. Breast cancer research and treatment. 156(1), 9-20 GREEN AR, ALESKANDARANY MA, AGARWAL D, ELSHEIKH S, NOLAN CC, DIEZ-RODRIGUEZ M, MACMILLAN RD, BALL GR, CALDAS C, MADHUSUDAN S, ELLIS IO and RAKHA EA, 2016. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. British journal of cancer. 114(8), 917-28 GREEN AR, SORIA D, POWE DG, NOLAN CC, ALESKANDARANY M, SZÁSZ MA, TŐKÉS AM, BALL GR, GARIBALDI JM, RAKHA EA, KULKA J and ELLIS IO, 2016. Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. Breast cancer research and treatment. 157(1), 65-75 PEREIRA B, CHIN SF, RUEDA OM, VOLLAN HK, PROVENZANO E, BARDWELL HA, PUGH M, JONES L, RUSSELL R, SAMMUT SJ, TSUI DW, LIU B, DAWSON SJ, ABRAHAM J, NORTHEN H, PEDEN JF, MUKHERJEE A, TURASHVILI G, GREEN AR, MCKINNEY S, OLOUMI A, SHAH S, ROSENFELD N, MURPHY L, BENTLEY DR, ELLIS IO, PURUSHOTHAM A, PINDER SE, BØRRESEN-DALE AL, EARL HM, PHAROAH PD, ROSS MT, APARICIO S and CALDAS C, 2016. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nature communications. 7, 11479 PEREIRA B, CHIN SF, RUEDA OM, VOLLAN HK, PROVENZANO E, BARDWELL HA, PUGH M, JONES L, RUSSELL R, SAMMUT SJ, TSUI DW, LIU B, DAWSON SJ, ABRAHAM J, NORTHEN H, PEDEN JF, MUKHERJEE A, TURASHVILI G, GREEN AR, MCKINNEY S, OLOUMI A, SHAH S, ROSENFELD N, MURPHY L, BENTLEY DR, ELLIS IO, PURUSHOTHAM A, PINDER SE, BØRRESEN-DALE AL, EARL HM, PHAROAH PD, ROSS MT, APARICIO S and CALDAS C, 2016. Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature communications. 7, 11908 ABDEL-FATAH TM, AGARWAL D, LIU DX, RUSSELL R, RUEDA OM, LIU K, XU B, MOSELEY PM, GREEN AR, POCKLEY AG, REES RC, CALDAS C, ELLIS IO, BALL GR and CHAN SY, 2016. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. The Lancet. Oncology. 17(7), 1004-18 ALESKANDARANY MA, GREEN AR, ASHANKYTY I, ELMOUNA A, DIEZ-RODRIGUEZ M, NOLAN CC, ELLIS IO and RAKHA EA, 2016. Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer. Breast cancer research and treatment. 158(2), 287-95 GREEN AR, SORIA D, POWE DG, NOLAN CC, ALESKANDARANY M, SZÁSZ MA, TŐKÉS AM, BALL GR, GARIBALDI JM, RAKHA EA, KULKA J and ELLIS IO, 2016. Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. Breast cancer research and treatment. 159(1), 199 ALSHAREEDA AT, NEGM OH, ALESKANDARANY MA, GREEN AR, NOLAN C, TIGHHE PJ, MADHUSUDAN S, ELLIS IO and RAKHA EA, 2016. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast cancer research and treatment. 159(1), 41-53 GREEN AR, SORIA D, STEPHEN J, POWE DG, NOLAN CC, KUNKLER I, THOMAS J, KERR GR, JACK W, CAMERON D, PIPER T, BALL GR, GARIBALDI JM, RAKHA EA, BARTLETT JM and ELLIS IO, 2016. Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. The journal of pathology. Clinical research. 2(1), 32-40 ALESKANDARANY MA, ABDULJABBAR R, ASHANKYTY I, ELMOUNA A, JERJEES D, ALI S, BULUWELA L, DIEZ-RODRIGUEZ M, CALDAS C, GREEN AR, ELLIS IO and RAKHA EA, 2016. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast cancer research and treatment. 159(2), 215-27 AGBOOLA AO, EBILI HO, IYAWE VO, BANJO AA, SALAMI BS, RAKHA EA, NOLAN C, ELLIS IO and GREEN AR, 2016. Tumour cell membrane laminin expression is associated with basal-like phenotype and poor survival in Nigerian breast cancer. The Malaysian journal of pathology. 38(2), 83-92
BESUSPARIS J, PLANCOULAINE B, RASMUSSON A, AUGULIS R, GREEN AR, ELLIS IO, LAURINAVICIENE A, HERLIN P and LAURINAVICIUS A, 2016. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer. Diagnostic pathology. 11(1), 82 AHMAD DA, NEGM OH, ALABDULLAH ML, MIRZA S, HAMED MR, BAND V, GREEN AR, ELLIS IO and RAKHA EA, 2016. Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. Breast cancer research and treatment. 159(3), 457-67 MUFTAH AA, ALESKANDARANY M, SONBUL SN, NOLAN CC, DIEZ RODRIGUEZ M, CALDAS C, ELLIS IO, GREEN AR and RAKHA EA, 2016. Further Evidence to Support Bimodality of Oestrogen Receptor Expression in Breast Cancer. Histopathology. (In Press.)
ARORA A, PARVATHANENI S, ALESKANDARANY MA, AGARWAL D, ALI R, ABDEL-FATAH TM, GREEN AR, BALL GR, RAKHA EA, ELLIS IO, SHARMA S and MADHUSUDAN S, 2016. Clinicopathological and functional significance of RECQL1 helicase in sporadic breast cancers. Molecular cancer therapeutics. (In Press.)
TOSS MS, PINDER SE, GREEN AR, THOMAS J, MORGAN DA, ROBERTSON JF, ELLIS IO and RAKHA EA, 2016. Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins? Histopathology. 70(5), 681-692 AGBOOLA AO, EBILI HO, IYAWE VO, BANJO AA, SALAMI BA, RAKHA EA, NOLAN CC, ELLIS IO and GREEN AR, 2016. Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. Pathology, research and practice. 213(1), 27-33 ABDULJABBAR R, AL-KAABI MM, NEGM OH, JERJEES D, MUFTAH AA, MUKHERJEE A, LAI CF, BULUWELA L, ALI S, TIGHE PJ, GREEN A, ELLIS I and RAKHA E, 2015. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Breast cancer research and treatment. 150(3), 511-22 ABDULJABBAR R, NEGM OH, LAI C, JERJEES DA, AL-KAABI M, HAMED MR, TIGHE PJ, BULUWELA L, MUKHERJEE A, GREEN AR, ALI S, RAKHA EA and ELLIS IO, 2015. Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Breast cancer research and treatment. 150(2), 335-46 JERJEES DA, NEGM OH, ALABDULLAH ML, MIRZA S, ALKAABI M, HAMEED MR, ABDULJABBAR R, MUFTAH A, NOLAN CC, GREEN AR, TIGHE PJ, BAND V, ELLIS IO and RAKHA EA, 2015. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Breast cancer research and treatment. 150(1), 91-103 ALESKANDARANY M, CARACAPPA D, NOLAN CC, MACMILLAN RD, ELLIS IO, RAKHA EA and GREEN AR, 2015. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Breast cancer research and treatment. 150(1), 81-90 AL-KAABI MM, ALSHAREEDA AT, JERJEES DA, MUFTAH AA, GREEN AR, ALSUBHI NH, NOLAN CC, CHAN S, CORNFORD E, MADHUSUDAN S, ELLIS IO and RAKHA EA, 2015. Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. British journal of cancer. 112(5), 901-11 ARORA A, ABDEL-FATAH TMA, AGARWAL D, DOHERTY R, MOSELEY PM, ALESKANDARANY MA, GREEN AR, BALL G, ALSHAREEDA AT, RAKHA EA, CHAN SYT, ELLIS IO and MADHUSUDAN S, 2015. Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. Molecular cancer therapeutics. 14(4), 1057-65 GREEN AR, CARACAPPA D, BENHASOUNA AA, ALSHAREEDA A, NOLAN CC, MACMILLAN RD, MADHUSUDAN S, ELLIS IO and RAKHA EA, 2015. Biological and clinical significance of PARP1 protein expression in breast cancer. Breast cancer research and treatment. 149(2), 353-62 ABDEL-FATAH TMA, MIDDLETON FK, ARORA A, AGARWAL D, CHEN T, MOSELEY PM, PERRY C, DOHERTY R, CHAN S, GREEN AR, RAKHA E, BALL G, ELLIS IO, CURTIN NJ and MADHUSUDAN S, 2015. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Molecular oncology. 9(3), 569-85 NELSON L, MCKEEN HD, MARSHALL A, MULRANE L, STARCZYNSKI J, STORR SJ, LANIGAN F, BYRNE C, ARTHUR K, HEGARTY S, ALI AA, FURLONG F, MCCARTHY HO, ELLIS IO, GREEN AR, RAKHA E, YOUNG L, KUNKLER I, THOMAS J, JACK W, CAMERON D, JIRSTRÖM K, YAKKUNDI A, MCCLEMENTS L, MARTIN SG, GALLAGHER WM, DUNN J, BARTLETT J, O'CONNOR D and ROBSON T, 2015. FKBPL: a marker of good prognosis in breast cancer. Oncotarget. (In Press.)
ALBANGHALI MA, GREEN AR, RAKHA E, ALESKANDARANY MA, NOLAN C, ELLIS IO and CHEUNG KL, 2015. Construction of tissue microarrays from core needle biopsy - a systematic literature review. Histopathology. (In Press.)
ONG CC, GIERKE S, PITT C, SAGOLLA M, CHENG CK, ZHOU W, JUBB AM, STRICKLAND L, SCHMIDT M, DURON SG, CAMPBELL DA, ZHENG W, DEHDASHTI S, SHEN M, YANG N, BEHNKE ML, HUANG W, MCKEW JC, CHERNOFF J, FORREST WF, HAVERTY PM, CHIN SF, RAKHA EA, GREEN AR, ELLIS IO, CALDAS C, O'BRIEN T, FRIEDMAN LS, KOEPPEN H, RUDOLPH J and HOEFLICH KP, 2015. Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast cancer research : BCR. 17, 59 ALSHAREEDA AT, NEGM OH, GREEN AR, NOLAN CC, TIGHE P, ALBARAKATI N, SULTANA R, MADHUSUDAN S, ELLIS IO and RAKHA EA, 2015. KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. British journal of cancer. 112(12), 1929-37 MAGNANI L, PATTEN DK, NGUYEN VT, HONG SP, STEEL JH, PATEL N, LOMBARDO Y, FARONATO M, GOMES AR, WOODLEY L, PAGE K, GUTTERY D, PRIMROSE L, FERNANDEZ GARCIA D, SHAW J, VIOLA P, GREEN A, NOLAN C, ELLIS IO, RAKHA EA, SHOUSHA S, LAM EW, GYŐRFFY B, LUPIEN M and COOMBES RC, 2015. The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer. Oncotarget. 6(26), 21878-91 ABDEL-FATAH TM, MCARDLE SE, AGARWAL D, MOSELEY PM, GREEN AR, BALL GR, POCKLEY AG, ELLIS IO, REES RC and CHAN SY, 2015. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 22(4), 905-14 PANDYA K, WYATT D, GALLAGHER B, SHAH D, BAKER A, BLOODWORTH J, ZLOBIN A, PANNUTI A, GREEN A, ELLIS IO, FILIPOVIC A, SAGERT J, RANA A, ALBAIN KS, MIELE L, DENNING MF and OSIPO C, 2015. PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 22(1), 175-86 ALSUBHI N, MIDDLETON F, ABDEL-FATAH TM, STEPHENS P, DOHERTY R, ARORA A, MOSELEY PM, CHAN SY, ALESKANDARANY MA, GREEN AR, RAKHA EA, ELLIS IO, MARTIN SG, CURTIN NJ and MADHUSUDAN S, 2015. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. Molecular oncology. 10(2), 213-23 ARORA A, ABDEL-FATAH TM, AGARWAL D, DOHERTY R, CROTEAU DL, MOSELEY PM, HAMEED K, GREEN A, ALESKANDARANY MA, RAKHA EA, PATTERSON K, BALL G, CHAN SY, ELLIS IO, BOHR VA, BRYANT HE and MADHUSUDAN S, 2015. Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. Carcinogenesis. 37(1), 63-71 NEGM OH, MUFTAH AA, ALESKANDARANY MA, HAMED MR, AHMAD DA, NOLAN CC, DIEZ-RODRIGUEZ M, TIGHE PJ, ELLIS IO, RAKHA EA and GREEN AR, 2015. Clinical utility of reverse phase protein array for molecular classification of breast cancer. Breast cancer research and treatment. 155(1), 25-35 GALLEGO-ORTEGA D, LEDGER A, RODEN DL, LAW AM, MAGENAU A, KIKHTYAK Z, CHO C, ALLERDICE SL, LEE HJ, VALDES-MORA F, HERRMANN D, SALOMON R, YOUNG AI, LEE BY, SERGIO CM, KAPLAN W, PIGGIN C, CONWAY JR, RABINOVICH B, MILLAR EK, OAKES SR, CHTANOVA T, SWARBRICK A, NAYLOR MJ, O'TOOLE S, GREEN AR, TIMPSON P, GEE JM, ELLIS IO, CLARK SJ and ORMANDY CJ, 2015. ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. PLoS biology. 13(12), e1002330 ARORA A, AGARWAL D, ABDEL-FATAH TM, LU H, CROTEAU DL, MOSELEY P, ALESKANDARANY MA, GREEN AR, BALL G, RAKHA EA, CHAN SY, ELLIS IO, WANG LL, ZHAO Y, BALAJEE AS, BOHR VA and MADHUSUDAN S, 2015. RECQL4 helicase has oncogenic potential in sporadic breast cancers. The Journal of pathology. 238(4), 495-501 ALSHAREEDA AT, NEGM OH, GREEN AR, NOLAN C, TIGHE P, ALBARAKATI N, SULTANA R, MADHUSUDAN S, ELLIS IO and RAKHA EA, 2014. SUMOylation proteins in breast cancer. Breast cancer research and treatment. 144(3), 519-30 ALBARAKATI N, ABDEL-FATAH TMA, DOHERTY R, RUSSELL R, AGARWAL D, MOSELEY P, PERRY C, ARORA A, ALSUBHI N, SEEDHOUSE C, RAKHA EA, GREEN A, BALL G, CHAN S, CALDAS C, ELLIS IO and MADHUSUDAN S, 2014. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Molecular oncology. 9(1), 204-17 ABDEL-FATAH TM, PERRY C, ARORA A, THOMPSON N, DOHERTY R, MOSELEY PM, GREEN AR, CHAN SY, ELLIS IO and MADHUSUDAN S, 2014. Is there a role for base excision repair in estrogen driven breast cancers? Antioxidants & redox signaling. 21(16), 2262-8 ABDEL-FATAH T, ARORA A, AGARWAL D, MOSELEY P, PERRY C, THOMPSON N, GREEN AR, RAKHA E, CHAN S, BALL G, ELLIS IO and MADHUSUDAN S, 2014. Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. Breast cancer research and treatment. 146(2), 309-20 ALESKANDARANY MA, NEGM OH, GREEN AR, AHMED MAH, NOLAN CC, TIGHE PJ, ELLIS IO and RAKHA EA, 2014. Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast cancer research and treatment. 145(2), 339-48 ABDEL-FATAH TMA, ARORA A, ALSUBHI N, AGARWAL D, MOSELEY PM, PERRY C, DOHERTY R, CHAN SYT, GREEN AR, RAKHA E, BALL G, ELLIS IO and MADHUSUDAN S, 2014. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts. Neoplasia (New York, N.Y.). 16(11), 982-91 JERJEES DA, ALABDULLAH M, ALKAABI M, ABDULJABBAR R, MUFTAH A, NOLAN C, GREEN AR, ELLIS IO and RAKHA EA, 2014. ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. Breast cancer research and treatment. 147(1), 25-37 AGBOOLA AOJ, BANJO AAF, ANUNOBI CC, AYOADE BA, DEJI-AGBOOLA AM, MUSA AA, ABDEL-FATAH T, NOLAN CC, RAKHA EA, ELLIS IO and GREEN AR, 2014. Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart. The Malaysian journal of pathology. 36(1), 3-17
JERJEES DA, ALABDULLAH M, GREEN AR, ALSHAREEDA A, MACMILLAN RD, ELLIS IO and RAKHA EA, 2014. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. Breast cancer research and treatment. 145(2), 317-30 GREEN AR, BARROS FFT, ABDEL-FATAH TMA, MOSELEY P, NOLAN CC, DURHAM AC, RAKHA EA, CHAN S and ELLIS IO, 2014. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast cancer research and treatment. 145(1), 33-44 BARROS FFT, ABDEL-FATAH TMA, MOSELEY P, NOLAN CC, DURHAM AC, RAKHA EA, CHAN S, ELLIS IO and GREEN AR, 2014. Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. Breast cancer research and treatment. 144(2), 273-85 AGBOOLA AOJ, MUSA AA, AYOADE BA, BANJO AA, ANUNOBI CC, DEJI-AGBOOLA AM, RAKHA EA, NOLAN C, ELLIS IO and GREEN AR, 2014. Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women. Pathology, research and practice. 210(1), 10-7 AGBOOLA A, MUSA A, BANJO A, AYOADE B, DEJI-AGBOOLA M, NOLAN C, RAKHA E, ELLIS I and GREEN A, 2014. PIASγ expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. Journal of clinical pathology. 67(4), 301-6 HO-YEN CM, GREEN AR, RAKHA EA, BRENTNALL AR, ELLIS IO, KERMORGANT S and JONES JL, 2014. C-Met in invasive breast cancer: is there a relationship with the basal-like subtype? Cancer. 120(2), 163-71 ULLENHAG GJ, AL-ATTAR A, MUKHERJEE A, GREEN AR, ELLIS IO and DURRANT LG, 2014. The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis. Journal of cancer research and clinical oncology. 141(3), 505-14 FILIPOVIĆ A, LOMBARDO Y, FARONATO M, ABRAHAMS J, ABOAGYE E, NGUYEN QD, D'AQUA BB, RIDLEY A, GREEN A, RAHKA E, ELLIS I, RECCHI C, PRZULJ N, SARAJLIĆ A, ALATTIA JR, FRAERING P, DEONARAIN M and COOMBES RC, 2014. Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells. Breast cancer research and treatment. 148(2), 455-62 VOLLAN HK, RUEDA OM, CHIN SF, CURTIS C, TURASHVILI G, SHAH S, LINGJÆRDE OC, YUAN Y, NG CK, DUNNING MJ, DICKS E, PROVENZANO E, SAMMUT S, MCKINNEY S, ELLIS IO, PINDER S, PURUSHOTHAM A, MURPHY LC, KRISTENSEN VN, , BRENTON JD, PHAROAH PD, BØRRESEN-DALE AL, APARICIO S and CALDAS C, 2014. A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Molecular oncology. 9(1), 115-27 MOORE KM, THOMAS GJ, DUFFY SW, WARWICK J, GABE R, CHOU P, ELLIS IO, GREEN AR, HAIDER S, BROUILETTE K, SAHA A, VALLATH S, BOWEN R, CHELALA C, ECCLES D, TAPPER WJ, THOMPSON AM, QUINLAN P, JORDAN L, GILLETT C, BRENTNALL A, VIOLETTE S, WEINREB PH, KENDREW J, BARRY ST, HART IR, JONES JL and MARSHALL JF, 2014. Therapeutic targeting of integrin αvβ6 in breast cancer. Journal of the National Cancer Institute. 106(8), XU Y, ZHANG H, LIT LC, GROTHEY A, ATHANASIADOU M, KIRITSI M, LOMBARDO Y, FRAMPTON AE, GREEN AR, ELLIS IO, ALI S, LENZ HJ, THANOU M, STEBBING J and GIAMAS G, 2014. The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁. Science signaling. 7(330), ra58 STEBBING J, ZHANG H, XU Y, LIT LC, GREEN AR, GROTHEY A, LOMBARDO Y, PERIYASAMY M, BLIGHE K, ZHANG W, SHAW JA, ELLIS IO, LENZ HJ and GIAMAS G, 2014. KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. Oncogene. 34(16), 2103-14 RAKHA EA, SORIA D, GREEN AR, LEMETRE C, POWE DG, NOLAN CC, GARIBALDI JM, BALL G and ELLIS IO, 2014. Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. British journal of cancer. 110(7), 1688-97 KHOSHNAW SM, RAKHA EA, ABDEL-FATAH T, NOLAN CC, HODI Z, MACMILLAN RD, ELLIS IO and GREEN AR, 2013. The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients. Breast cancer research and treatment. 137(1), 139-53 BAKER BG, BALL GR, RAKHA EA, NOLAN CC, CALDAS C, ELLIS IO and GREEN AR, 2013. Lack of expression of the proteins GMPR2 and PPARα are associated with the basal phenotype and patient outcome in breast cancer. Breast cancer research and treatment. 137(1), 127-37 MIRZA S, RAKHA EA, ALSHAREEDA A, MOHIBI S, ZHAO X, KATAFIASZ BJ, WANG J, GURUMURTHY CB, BELE A, ELLIS IO, GREEN AR, BAND H and BAND V, 2013. Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients. Breast cancer research and treatment. 137(3), 721-31 GILL MS, PAISH EC, RONAN J, GREEN AR, ELLIS IO and LEE AHS, 2013. Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 21(1), 90-3 GREEN, AR, POWE, DG, RAKHA, EA, SORIA, D, LEMETRE, C, NOLAN, CC, BARROS, FFT, MACMILLAN, RD, GARIBALDI, JM, BALL, GR and OTHERS, 2013. Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers British journal of cancer. 109(7), 1886-1894 AGBOOLA AOJ, BANJO AAF, ANUNOBI CC, SALAMI B, AGBOOLA MD, MUSA AA, NOLAN CC, RAKHA EA, ELLIS IO and GREEN AR, 2013. Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. ISRN oncology. 2013, 675051 AGBOOLA AJ, MUSA AA, WANANGWA N, ABDEL-FATAH T, NOLAN CC, AYOADE BA, OYEBADEJO TY, BANJO AA, DEJI-AGBOOLA AM, RAKHA EA, GREEN AR and ELLIS IO, 2013. Too many statistical errors for meaningful interpretation. Response to letter to the editor. Breast cancer research and treatment. 138(2), 645-50
ALSHAREEDA AT, NEGM OH, ALBARAKATI N, GREEN AR, NOLAN C, SULTANA R, MADHUSUDAN S, BENHASOUNA A, TIGHE P, ELLIS IO and RAKHA EA, 2013. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. Breast cancer research and treatment. 139(2), 301-10 JUNG, Y., ABDEL-FATAH, T. M., CHAN, S. Y., NOLAN, C. C., GREEN, A. R., ELLIS, I. O., LI, L., HUANG, B., LU, J., XU, B., CHEN, L., MA, R. Z., ZHANG, M., WANG, J., WU, Z., ZHU, T., PERRY, J. K., LOBIE, P. E. and LIU, D. X., 2013. SHON is a novel estrogen-regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy: Cancer Res Cancer Res. 73(23), 6951-62 GREEN, A. R., POWE, D. G., RAKHA, E. A., SORIA, D., LEMETRE, C., NOLAN, C. C., BARROS, F. F., MACMILLAN, R. D., GARIBALDI, J. M., BALL, G. R. and ELLIS, I. O., 2013. Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers: Br J Cancer Br J Cancer. 109(7), 1886-94 ALSHAREEDA, A. T., SORIA, D., GARIBALDI, J. M., RAKHA, E., NOLAN, C., ELLIS, I. O. and GREEN, A. R., 2013. Characteristics of basal cytokeratin expression in breast cancer: Breast Cancer Res Treat Breast Cancer Res Treat. 139(1), 23-37 ALSHAREEDA AT, SORIA D, GARIBALDI JM, RAKHA E, NOLAN C, ELLIS IO and GREEN AR, 2013. Characteristics of basal cytokeratin expression in breast cancer. Breast cancer research and treatment. 139(1), 23-37 STORR, S.J., LEE, K.W., WOOLSTON, C.M., SAFUAN, S., GREEN, A.R., MACMILLAN, R.D., BENHASOUNA, A., PARR, T., ELLIS, I.O. and MARTIN, S.G., 2012. Calpain system protein expression in basal-like and triple-negative invasive breast cancer Annals of Oncology: Official Journal of the European Society for Medical Oncology. 23(9), 2289-2296 AGBOOLA AJ, MUSA AA, WANANGWA N, ABDEL-FATAH T, NOLAN CC, AYOADE BA, OYEBADEJO TY, BANJO AA, DEJI-AGBOOLA AM, RAKHA EA, GREEN AR and ELLIS IO, 2012. Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast cancer research and treatment. 135(2), 555-69 KHOSHNAW SM, RAKHA EA, ABDEL-FATAH TM, NOLAN CC, HODI Z, MACMILLAN DR, ELLIS IO and GREEN AR, 2012. Loss of Dicer expression is associated with breast cancer progression and recurrence. Breast cancer research and treatment. 135(2), 403-13 ALSHAREEDA AT, RAKHA EA, NOLAN CC, ELLIS IO and GREEN AR, 2012. Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. Breast cancer research and treatment. 134(2), 519-29 RAKHA EA, TUN M, JUNAINAH E, ELLIS IO and GREEN A, 2012. Encapsulated papillary carcinoma of the breast: a study of invasion associated markers. Journal of clinical pathology. 65(8), 710-4 WISHART GC, BAJDIK CD, DICKS E, PROVENZANO E, SCHMIDT MK, SHERMAN M, GREENBERG DC, GREEN AR, GELMON KA, KOSMA V, OLSON JE, BECKMANN MW, WINQVIST R, CROSS SS, SEVERI G, HUNTSMAN D, PYLKÄS K, ELLIS I, NIELSEN TO, GILES G, BLOMQVIST C, FASCHING PA, COUCH FJ, RAKHA E, FOULKES WD, BLOWS FM, BÉGIN LR, VAN'T VEER LJ, SOUTHEY M, NEVANLINNA H, MANNERMAA A, COX A, CHEANG M, BAGLIETTO L, CALDAS C, GARCIA-CLOSAS M and PHAROAH PDP, 2012. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. British journal of cancer. 107(5), 800-7 ALESKANDARANY MA, NEGM OH, RAKHA EA, AHMED MAH, NOLAN CC, BALL GR, CALDAS C, GREEN AR, TIGHE PJ and ELLIS IO, 2012. TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. Breast cancer research and treatment. 136(2), 419-27 NOUF AL-SUBHI, REEM ALI, TAREK ABDEL-FATAH, PAUL M. MOSELEY, STEPHEN Y.T. CHAN, ANDREW R. GREEN, IAN O. ELLIS, EMAD A. RAKHA and SRINIVASAN MADHUSUDAN, Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy Breast Cancer Research and Treatment. 169, HA LINH NGUYEN, TATJANA GEUKENS, MARION MAETENS, SAMUEL APARICIO, AYSE BASSEZ, AKE BORG, JANE BROCK, ANNEGIEN BROEKS, CARLOS CALDAS, FATIMA CARDOSO, MAXIM DE SCHEPPER, MAURO DELORENZI, CAROLINE A. DRUKKER, ANNUSKA M. GLAS, ANDREW R. GREEN, EDOARDO ISNALDI, JÓRUNN EYFJÖRÐ, HAZEM KHOUT, STIAN KNAPPSKOG, SAVITRI KRISHNAMURTHY, SUNIL R. LAKHANI, ANITA LANGEROD, JOHN W.M. MARTENS, AMY E. MCCART REED, LEIGH MURPHY, STEFAN NAULAERTS, SERENA NIK-ZAINAL, INES NEVELSTEEN, PATRICK NEVEN, MARTINE PICCART, CORALIE PONCET, KEVIN PUNIE, COLIN PURDIE, EMAD A. RAKHA, ANDREA RICHARDSON, EMIEL RUTGERS, ANNE VINCENT-SALOMON, PETER T. SIMPSON, MARJANKA K. SCHMIDT, CHRISTOS SOTIRIOU, PAUL N. SPAN, KIAT TEE BENITA TAN, ALASTAIR THOMPSON, STEFANIA TOMMASI, KAREN VAN BAELEN, MARC VAN DE VIJVER, STEVEN VAN LAERE, LAURA VAN’T VEER, GIUSEPPE VIALE, ALAIN VIARI, HANNE VOS, ANKE T. WITTEVEEN, HANS WILDIERS, GIUSEPPE FLORIS, ABHISHEK D. GARG, ANN SMEETS, DIETHER LAMBRECHTS, ELIA BIGANZOLI, FRANÇOIS RICHARD and CHRISTINE DESMEDT, Obesity-associated changes in molecular biology of primary breast cancer Nature Communications. 14, MARINA CISCAR, EVA M TRINIDAD, GEMA PEREZ‐CHACON, MANSOUR ALSALEEM, MARIA JIMENEZ, MARIA J JIMENEZ‐SANTOS, HECTOR PEREZ‐MONTOYO, ADRIAN SANZ‐MORENO, ANDREA VETHENCOURT, MICHAEL TOSS, ANNA PETIT, MARIA T SOLER‐MONSO, VICTOR LOPEZ, JORGE GOMEZ‐MIRAGAYA, CLARA GOMEZ‐ALEZA, LACEY E DOBROLECKI, MICHAEL T LEWIS, ALEJANDRA BRUNA, SILVANA MOURON, MIGUEL QUINTELA‐FANDINO, FATIMA AL‐SHAHROUR, ANTONIO MARTINEZ‐ARANDA, ANGELS SIERRA, ANDREW R GREEN, EMAD RAKHA and EVA GONZALEZ‐SUAREZ, RANK is a poor prognosis marker and a therapeutic target in ER ‐negative postmenopausal breast cancer EMBO Molecular Medicine. 15, MARINA CISCAR, EVA M TRINIDAD, GEMA PEREZ‐CHACON, MANSOUR ALSALEEM, MARIA JIMENEZ, MARIA J JIMENEZ‐SANTOS, HECTOR PEREZ‐MONTOYO, ADRIAN SANZ‐MORENO, ANDREA VETHENCOURT, MICHAEL TOSS, ANNA PETIT, MARIA T SOLER‐MONSO, VICTOR LOPEZ, JORGE GOMEZ‐MIRAGAYA, CLARA GOMEZ‐ALEZA, LACEY E DOBROLECKI, MICHAEL T LEWIS, ALEJANDRA BRUNA, SILVANA MOURON, MIGUEL QUINTELA‐FANDINO, FATIMA AL‐SHAHROUR, ANTONIO MARTINEZ‐ARANDA, ANGELS SIERRA, ANDREW R GREEN, EMAD RAKHA and EVA GONZALEZ‐SUAREZ, RANK is a poor prognosis marker and a therapeutic target in ER ‐negative postmenopausal breast cancer EMBO Molecular Medicine. 15, ESTHER DANENBERG, HELEN BARDWELL, VITO R.T. ZANOTELLI, ELENA PROVENZANO, SUET FEUNG CHIN, OSCAR M. RUEDA, ANDREW GREEN, EMAD RAKHA, SAMUEL APARICIO, IAN O. ELLIS, BERND BODENMILLER, CARLOS CALDAS and H. RAZA ALI, Breast tumor microenvironment structures are associated with genomic features and clinical outcome Nature Genetics. 54, LUTFI H. ALFARSI, ROKAYA EL ANSARI, MADELEINE L. CRAZE, OMAR J. MOHAMMED, BRENDAH K. MASISI, IAN O. ELLIS, EMAD A. RAKHA and ANDREW R. GREEN, SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer Breast Cancer Research and Treatment. 189, LUTFI H. ALFARSI, ROKAYA EL ANSARI, MADELEINE L. CRAZE, BRENDAH K. MASISI, IAN O. ELLIS, EMAD A. RAKHA and ANDREW R. GREEN, PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer BMC Cancer. 20, LUTFI H. ALFARSI, ROKAYA EL-ANSARI, MADELEINE L. CRAZE, BRENDAH K. MASISI, OMAR J. MOHAMMED, IAN O. ELLIS, EMAD A. RAKHA and ANDREW R. GREEN, Co-expression effect of SLC7A5/SLC3A2 to predict response to endocrine therapy in oestrogen- receptor-positive breast cancer International Journal of Molecular Sciences. 21,